Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G for Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX).
- Disclosed ownership: 8%.
- Date of event: 31 Dec 2024.
ORBIMED ADVISORS LLC - 31 Dec 2024 SCHEDULE 13G Report for Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- ORBIMED ADVISORS LLC
- Symbol
- FBRX
- Shares outstanding
- 6,375,000 shares
- Disclosed Ownership
- 510,000 shares
- Ownership
- 8%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 16:22:11 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 8% ownership in Forte Biosciences, Inc. Common Stock, par value $0.001 per share (FBRX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 8% | 510,000 | 0 | 510,000 | /s/ Carl L. Gordon | Carl L. Gordon/Member | |
| ORBIMED CAPITAL LLC | 1.4% | 90,000 | 90,000 | 0 | /s/ Carl L. Gordon | Carl L. Gordon/Member |